The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

n, D.C. 20549 OMB Number: 323

OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

OMB APPROVAL

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	None	Entity Type
0001832415	Mountain Cre	est Acquisition Corp II	X Corporation
Name of Issuer		•	Limited Partnership
Better Therapeutics, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Or	ganization		General Partnership
DELAWARE			
Year of Incorporation/Organiza	tion		Business Trust
Over Five Years Ago			Other (Specify)
X Within Last Five Years (Spe	ecify Year) 2020		
Yet to Be Formed			
2. Principal Place of Business	s and Contact Information		
Name of Issuer			
Better Therapeutics, Inc.			
Street Address 1		Street Address 2	
548 MARKET ST. #49404			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN FRANCISCO	CALIFORNIA	94101	(415) 887-2311
3. Related Persons			
Last Name	First Name		Middle Name
Karbe	Frank		
Street Address 1	Street Address 2		
548 Market St. #49404			
City	State/Province/Co	ountry	ZIP/PostalCode
San Francisco	CALIFORNIA		94104
Relationship: X Executive Off	icer X Director Promoter		
Clarification of Response (if Ne	cessary):		
Last Name	First Name		Middle Name
Perry	David		
Street Address 1	Street Address 2		
548 Market St. #49404			
City	State/Province/Co	ountry	ZIP/PostalCode
San Francisco	CALIFORNIA		94104
Relationship: X Executive Off	icer X Director Promoter		
Clarification of Response (if Ne	cessary):		
Last Name	First Name		Middle Name
Berman	Mark		
Street Address 1	Street Address 2		
548 Market St. #49404			
City	State/Province/Co	ountry	ZIP/PostalCode
San Francisco	CALIFORNIA		94104
Relationship: X Executive Off	icer Director Promoter		

Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Wynholds	Kristin		
Street Address 1	Street Address 2		
548 Market St. #49404			
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: X Executive Office		0.120.	
Clarification of Response (if Neces			
Last Name	First Name	Middle Name	
Heinen	Mark	Middle Name	
Street Address 1 548 Market St. #49404	Street Address 2		
	State / Dravings / Country	ZIP/PostalCode	
City San Francisco	State/Province/Country CALIFORNIA	94104	
_		34104	
Relationship: X Executive Office			
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Carmona	Richard		
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: Executive Office	r X Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Armanino	Andrew		
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: Executive Office	r X Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Lavizzo-Mourey	Risa		
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: Executive Office	r X Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Parker	Geoffrey		
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: Executive Office			
Clarification of Response (if Neces			
Last Name	First Name	Middle Name	

Granger	Elder		
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: Executive Officer X Direct	ctor Promoter		
Clarification of Response (if Necessary):			
4. Industry Group			
Agriculture	Health Care	Retailing	
Banking & Financial Services	X Biotechnology	Restaurants	
Commercial Banking	Health Insurance		
Insurance		Technology	
Investing	Hospitals & Physicians	Computers	
Investment Banking	Pharmaceuticals	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
Is the issuer registered as	Manufacturing	Travel	
an investment company under	Real Estate		
the Investment Company Act of 1940?	Commercial	Airlines & Airports	
		Lodging & Conventions	
YesNo	Construction	Tourism & Travel Services	
Other Banking & Financial Services	REITS & Finance	Other Travel	
Business Services	Residential		
Energy		Other	
Coal Mining	Other Real Estate		
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
5. Issuer Size			
Revenue Range OR	Aggregate Net Asset Va	alue Range	
No Revenues	No Aggregate Net A	sset Value	
\$1 - \$1,000,000	\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,00	0,000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,0	00,000	
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,	000,000	
Over \$100,000,000	Over \$100,000,000		
X Decline to Disclose	Decline to Disclose		
	Not Applicable		
Not Applicable			
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)		
	Investment Comp	any Act Section 3(c)	
	Section 3(c)(1)	Section 3(c)(9)	
Rule 504(b)(1) (not (i), (ii) or (iii))			
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)	
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)	
X Rule 506(b)			
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		

7. Type of Filing			
X New Notice Date of First Sale 2023-07-27 First Sale Yet to Amendment	o Occur		
8. Duration of Offering			
Does the Issuer intend this offering to last more than one year?	Yes X No		
9. Type(s) of Securities Offered (select all that apply)			
 X Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or CRight to Acquire Security 	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)		
10. Business Combination Transaction			
Is this offering being made in connection with a business combina merger, acquisition or exchange offer?	ation transaction, such as a Yes X No		
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside investor \$0 USD			
12. Sales Compensation			
Chardan Capital Markets LLC (Associated) Broker or Dealer X None None Street Address 1 17 State Street, Suite 2130 City New York State(s) of Solicitation (soloct all that apply)	Recipient CRD Number None 120128 (Associated) Broker or Dealer CRD Number None Street Address 2 State/Province/Country NEW YORK X Foreign/non-US	ZIP/Postal Code 10004	
Recipient Titan Partners Group LLC, a division of American Capital Partners, LLC (Associated) Broker or Dealer X None None Street Address 1 7 World Trade Center, 46th Floor City New York State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Recipient CRD Number None 44656 (Associated) Broker or Dealer CRD Number X None None Street Address 2 State/Province/Country NEW YORK X Foreign/non-US	ZIP/Postal Code 10007	
ARKANSAS			

G. Eli Giu III
COLORADO
CONNECTICUT
FLORIDA
ILLINOIS
NEW JERSEY
NEW YORK
TEXAS
WASHINGTON
13. Offering and Sales Amounts
Total Offering Amount \$2,114,998 USD or Indefinite
Total Amount Sold \$2,114,998 USD
Total Remaining to be Sold \$0 USD or Indefinite
Clarification of Response (if Necessary):

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited

enter the number of such non-accredited investors who already have invested in the offering.

investors, enter the total number of investors who already have invested in the offering: 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$126,900 USD Estimate

Private placement of 2,897,654 shares of common stock at a price of \$0.7299 per share.

Finders' Fees \$0 USD | Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

14. Investors

CALIFORNIA

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Better Therapeutics, Inc.	/s/ Mark Heinen	Mark Heinen	Chief Financial Officer	2023-08-11

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.